New drug duo targets tough lymphoma
NCT ID NCT06883526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, ZG005 and gecacitinib, in 60 adults with relapsed or refractory lymphoma (cancer of the lymph system). The first part finds a safe dose; the second part checks if the combo shrinks tumors. Participants must have confirmed lymphoma that has not responded to prior therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a drug duo outsmart resistant lymphomas?
- New PET tracer could sharpen diagnosis of blood cancers
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- New dashboard aims to make leukemia trials more inclusive